Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

751
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
751
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

1.2K
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
1.2K
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

886
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
886
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

1.7K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.7K
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

4.7K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.7K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

621
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
621

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Catheter Ablation versus Antiarrhythmic Drug Therapy for Atrial Fibrillation (CABANA) Trial: Study Rationale and Design.

American heart journal·2018
Same author

Identifying Subpopulations with Distinct Response to Treatment Using Plasma Biomarkers in Acute Heart Failure: Results from the PROTECT Trial : Differential Response in Acute Heart Failure.

Cardiovascular drugs and therapy·2017
Same author

Hospitalization for Recently Diagnosed Versus Worsening Chronic Heart Failure: From the ASCEND-HF Trial.

Journal of the American College of Cardiology·2017
Same author

A network analysis to compare biomarker profiles in patients with and without diabetes mellitus in acute heart failure.

European journal of heart failure·2017
Same author

Biomarker Profiles of Acute Heart Failure Patients With a Mid-Range Ejection Fraction.

JACC. Heart failure·2017
Same author

Development of Acute Decompensated Heart Failure Therapies: Is the Journey Over?

JACC. Heart failure·2017

Related Experiment Video

Updated: Apr 28, 2026

Induction and Phenotyping of Acute Right Heart Failure in a Large Animal Model of Chronic Thromboembolic Pulmonary Hypertension
07:41

Induction and Phenotyping of Acute Right Heart Failure in a Large Animal Model of Chronic Thromboembolic Pulmonary Hypertension

Published on: March 17, 2022

2.4K

Charting a roadmap for heart failure biomarker studies.

Tariq Ahmad1, Mona Fiuzat1, Michael J Pencina2

  • 1Division of Cardiology, Duke University Medical Center, Durham, North Carolina; Duke Clinical Research Institute, Durham, North Carolina.

JACC. Heart Failure
|June 16, 2014
PubMed
Summary
This summary is machine-generated.

Developing reliable heart failure biomarkers requires a systematic approach. A proposed consortium will improve biomarker study quality, clinical translation, and therapeutic selection for heart failure patients.

Keywords:
biomarkersheart failurestudies

More Related Videos

Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System
02:47

Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System

Published on: May 12, 2023

2.2K

Related Experiment Videos

Last Updated: Apr 28, 2026

Induction and Phenotyping of Acute Right Heart Failure in a Large Animal Model of Chronic Thromboembolic Pulmonary Hypertension
07:41

Induction and Phenotyping of Acute Right Heart Failure in a Large Animal Model of Chronic Thromboembolic Pulmonary Hypertension

Published on: March 17, 2022

2.4K
Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System
02:47

Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System

Published on: May 12, 2023

2.2K

Area of Science:

  • Cardiovascular Medicine
  • Biomarker Discovery
  • Translational Research

Background:

  • Heart failure (HF) diagnosis and treatment are complex, involving interconnected molecular pathways.
  • Biomarkers offer potential for HF prognostication and therapy selection, but inconsistent methodologies hinder clinical translation.
  • Current literature lacks standardized approaches, leading to variable quality in biomarker studies.

Purpose of the Study:

  • To propose a systematic, collaborative approach for studying novel heart failure biomarkers.
  • To enhance the quality and clinical utility of biomarker research in heart failure.
  • To facilitate the translation of biomarker discoveries from bench to bedside.

Main Methods:

  • Review and synthesis of input from academia, industry, and governmental agencies.
  • Proposal of a systematized approach with specific quality measures for biomarker studies.
  • Recommendation for advanced statistical methodologies and collaborative efforts.

Main Results:

  • A framework for grading biomarker studies based on quality, not just results.
  • Emphasis on the need for collaboration between clinical investigators and statisticians.
  • Proposal for a heart failure biomarker consortium for pooled analysis and trial design.

Conclusions:

  • A standardized, quality-driven approach is crucial for advancing heart failure biomarker research.
  • Collaboration and advanced statistical methods are essential for distilling complex data into actionable clinical information.
  • A dedicated consortium can accelerate the validation and clinical implementation of novel heart failure biomarkers.